ÂÜÀòÂÒÂ×

Mr. Bazemore has served as President, Chief Executive Officer and Director of Epizyme since September 2015.. Prior to joining Epizyme, he served as Chief Operating Officer of Synageva, where he established the company’s global commercial and medical organization to support the first product launch and helped lead the broader transition to a sustainable commercial enterprise, through its acquisition in July 2015. With more than 25 years of experience across the life sciences industry, Mr. Bazemore held several senior leadership positions at Johnson & Johnson, including President of Janssen Biotech, where he led the successful launches of numerous products and indications, including the U.S. launches of the oncology therapies ZYTIGA® and IMBRUVICA®, and guided the company’s worldwide immunology portfolio strategy. Prior to Johnson & Johnson, he worked at Merck & Co., Inc. for 11 years where he held roles of increasing responsibility, including the launch of SINGULAIR® in the U.S. He is a member of the Board of Directors of Ardelyx, Inc., and was a Board member of Neon Therapeutics. He earned a B.S. in biochemistry from the University of Georgia.